Literature DB >> 12140199

Eliminating onchocerciasis as a public health problem: the beginning of the end.

D Etya'alé1.   

Abstract

Onchocerciasis is one of the diseases targeted by Vision 2020. It is the world's second leading infectious cause of blindness, responsible for at least one million blind or severely visually disabled people. The Onchocerciasis Control Programme (OCP) in sub-Saharan Africa will be closed down in 2002, after 27 years of operation. This is the clearest indication that the prospects of eliminating onchocerciasis as a public health problem may be achieved by the end of this decade. The programme's potential now is to serve as a model of global and multiple partnership, to address other poverty related, serious and intractable problems such as needless blindness in the world.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12140199      PMCID: PMC1771252          DOI: 10.1136/bjo.86.8.844

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  2 in total

Review 1.  Mectizan as a stimulus for development of novel partnerships: the international organization's perspective.

Authors:  D E Etya'alé
Journal:  Ann Trop Med Parasitol       Date:  1998-04

Review 2.  Economic impact of onchocerciasis control through the African Programme for Onchocerciasis Control: an overview.

Authors:  B Benton
Journal:  Ann Trop Med Parasitol       Date:  1998-04
  2 in total
  4 in total

Review 1.  WIPO Re:Search: Accelerating anthelmintic development through cross-sector partnerships.

Authors:  Roopa Ramamoorthi; Katy M Graef; Jennifer Dent
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-09-19       Impact factor: 4.077

2.  Knowledge, attitude and practice of community drug distributors' about onchocerciasis and community directed treatment with ivermectin in Quara district, North Western Ethiopia.

Authors:  Fitsum Weldegebreal; Girmay Medhin; Zemichael Weldegebriel; Mengistu Legesse
Journal:  BMC Res Notes       Date:  2016-04-06

Review 3.  Current therapeutic applications and pharmacokinetic modulations of ivermectin.

Authors:  Khan Sharun; T S Shyamkumar; V A Aneesha; Kuldeep Dhama; Abhijit Motiram Pawde; Amar Pal
Journal:  Vet World       Date:  2019-08-08

Review 4.  Marine Actinomycetes, New Sources of Biotechnological Products.

Authors:  Sveta V Jagannathan; Erika M Manemann; Sarah E Rowe; Maiya C Callender; William Soto
Journal:  Mar Drugs       Date:  2021-06-25       Impact factor: 5.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.